Panobinostat, bortezomib, and dexamethasone

Jatin J. Shah, MD; Maria-Victoria Mateos, MD, PhD; and Andrew Spencer, MD, share their experiences using the triplet combination of panobinostat, bortezomib, and dexamethasone in relapsed/refractory multiple

At the 20th Congress of the European Hematology Association (EHA), Jesús F. San Miguel, MD, of the Clínica Universidad de Navarra, Navarra, Spain, discusses the results of a predefined subgroup analysis of the PANORAMA 1 trial, which evaluated the histone deacetylase inhibitor, panobinostat, plus bortezomib